France is one of the highest medicinal drug consumers in Europe. Drug-related expenditure by the Assurance Maladie was 73.1 billion FF in 1999. Since 1999, drug coding has allowed the Assurance Maladie to identify the total costs reimbursed for each proprietary pharmaceutical product; the code used in the Caisse Nationale dÕAssurance Maladie des Travailleurs Salari s (CNAMTS) (Assurance Maladie National Funds for Employees) is the CIP code. Granting the right of substitution to pharmacists was designed to reduce the total cost of pharmaceutical consumption in France for identical prescription volumes and drug consumption. In order to measure the effects of this regulatory procedure, the Minister of Health asked us to undertake a study of practitioners in order to establish the extent of their involvement in prescribing and substituting generic medicinal drugs.
• The right of substitution granted to pharmacists by the 1999 decree allows them to replace prescribed reference drugs or generic versions with other generic drugs belonging to the same group. The group consists of the reference drug and its generic versions. In exceptional cases, the pharmacists may substitute a generic drug with a reference drug if the additional cost to the Assurance Maladie is less than 0.50 FF. The term "not substitutable" may be used by the prescriber to exclude any possibility that the drug will be substituted by the pharmacist.
The databases used
A listing exists of all of the generic drugs available in France; this was designed and is updated regularly by the Agence Fran aise de S curit Sanitaire des Produits de Sant (AFSSAPS) (French Agency for Sanitary Safety of Health Products). This listing also states the presence of excipients with noted effects for those drugs which contain them. The pharmacist must then take account of these excipients before making any substitution. The AFSSAPS listing used for this study dates from June 2000. It contains 99 active substances, 220 generic groups, 229 reference medical drugs and 867 generic drugs.
The Sempex database contains all of the medical drugs and devices which may be used in France, together with their pharmaceutical, medical and economic characteristics. This is updated every month and each medicinal product is identified by its CIP code.
Methodology
• The first study was designed to calculate the actual substitution and prescription costs for generic medicinal products in France. We then selected a province, although this is not representative of the whole of France. The study methodology involved examining claims for reimbursement from the coded pharmacies, sent electronically to the Caisse Primaire de la Seine Saint Denis, on 15th June 2000. This allowed us to establish the percentage of generic drugs reimbursed, the percentage of generic drugs prescribed and the percentage of generic drugs which were substituted. We also studied the determining factors for prescription and substitution.
• The second study was designed to record the frequency of prescriptions of generic drugs, the substitution frequency for reference drugs and the patientsÕ behavioural response to prescription or substitution. In order to do this, we sent a questionnaire to a representative sample of 4,000 private medical practitioners and 3,475 dispensing phar
Statistical methods
In addition to age and sex, the stratification variables used for the patients were: exemption status from personal contributions (ETM), universal sickness cover (CMU) and the reference doctor . We did not take into account repeat prescriptions in calculating the percentage of prescriptions for and substitutions with generic drugs. The sums billed and those reimbursed by the Assurance Maladie for the medicinal drugs were then calculated from the public price of the drug. Percentage values were compared by the χ2 test and logistic regression was used to test for simultaneous multiple determinants of prescription or substitution. The odds ratio was calculated for determinants which were significant. The statistical probability threshold was set at 5% and statistical analysis was performed on SAS  software (Statistic Analysis System).
General characteristics
We studied a total of 25,422 prescriptions from 6,578 patients. Sixty percent of the patients were female and 30% were exempted from personal contributions, 15% received CMU and 5% had a reference medical practitioner. The prescriptions were written by a total of 2,273 doctors. One-hundred-and-forty-eight pharmacists took part in dispensing the drugs which were prescribed. Of all of the prescriptions issued, 3,902 (15.35%) were on the AFSSAPS listing. Twelve pharmaco-therapeutic classes were identified for all of the drugs which were dispensed. Two of these accounted for almost 50% of the prescriptions (central nervous system and cardiovascular system). 6.8% of the drug prescriptions were made under their international non-proprietary name (INN). The term Ônot substitutableÕ was used in less than 1% of the prescriptions for reference drugs.
The drug reimbursement claims came from 2,656 patients. Generic drugs were prescribed to 1,086 patients (41%). Of these, 56% were female and 33% were exempted from personal contributions. The average patient age was 44 years old. Reference drugs were dispensed to 1,968 patients, 58% of whom were women and 40% were exempted from personal contributions. The mean patient age was 50 years old.
Of the 3,902 drug prescriptions dispensed which belonged to the AFSSAPS listing, 1,257 were for generic drugs. 53.5% of these were prescribed, whereas 29.9% were substituted. 16.7% of the prescriptions dispensed were renewal prescriptions and could not be studied as the medical prescription was not available.
When we look at all of the proprietary drugs in the listing, it may be seen that this contains 18.2% (672/3,692) of generic drugs which were prescribed and 12.4% (375/3,026) of generic drugs which were substituted.
Behavioural response of patients to prescription or substitution of generic drugs
The practitioner declaration survey showed that information about generic drugs comes mostly from the Assurance Maladie funds or from the pharmaceutical companies. Approximately 20 per cent of prescriptions include at least one generic drug. The term "not-substitutable" is very rarely used by the medical practitioner; the doctors reported that they use this measure for less than 5% of cases. The criteria for substitution and generic prescription reported by the practitioners were firstly acceptance by the patient, the patient's age and level of understanding, and secondly, the difference in cost between the reference and generic drugs. The pharmacists and doctors reported that the patient refusal rate was approximately 15%.
Conclusion
The results above were obtained from data from one province which has a large number of people covered by social insurance. Its population, however, is not representative of the whole of France (the percentage CMU and ETM rates are higher than national figures). At present, a study on substitution in France requires us to return to the doctor's prescription as the Assurance Maladie reimbursement databases only contain the proprietary products dispensed to the patients. It is therefore very difficult to perform this type of study on a national scale. Right of replacement granted to pharmacists since May 1999 is gradually being applied. One year on, it may be seen that the prescription rate for generic drugs (18.2%) remains higher than the substitution rate (12.4%). Substitution allows the pharmaceutical act of dispensing drugs to have values attached to it. The use of generic drugs represents 32% of the drugs in the listing.
Compared to a study performed in the same province two years earlier, we see an increase in the rate of use of generic drugs, which may be explained by three factors: the increase in generic drugs available, replacement by pharmacists and increase in the prescription by doctors. The latter two factors may result from information campaigns conducted by the Assurance Maladie funds towards health care professionals. The amount reimbursed for generic drugs made up to 3.7% of the total amount reimbursed compared to 25.5% in our study. The savings in sums reimbursed by the Assurance Maladie are 10%; this could be increased to 29.6% if generic drugs were prescribed systematically and to 37.3% if systematic substitution of reference medicinal products took place.
The scope for advance in the use of generic agents in France is still high: according to some studies, 35% of drugs used in the United Kingdom and in Germany are generics, and 45% in the United States and Canada. In order to promote the use of generic agents better in France, we must: 
Determinants for substitution by the pharmacist
3,020 reference drugs could have been substituted; the right of substitution was only used for 375 of these, representing a substitution rate of 12.4%. Taking account of all the stratification variables for each prescription of a medicinal product which was substituted, it may be seen that substitution occurs more frequently in patients with CMU (OR = 3.63; p < 0.001), in male patients (OR = 1.24; p < 0.001) and in patients less than 65 years old (OR = 1.54; p < 0.001). Exemption from personal contributions was not a determining factor for substitution.
Determinants for prescribing generic drugs by the doctor
3,692 reference drugs could have been prescribed; the generic drug prescription rate was 18.2%. Taking account of all the stratification variables for each prescription of a medicinal product, it may be seen that generic drugs are more often prescribed to patients with CMU (OR = 2.85; p < 0.001), to patients exempted from personal contributions (OR = 1.22; p < 0.001) and to patients with a reference medical practitioner (OR = 1.08; p < 0.001). Sex and age were not determining factors for prescribing generic drugs.
Breakdown of costs incurred for proprietary products in the AFSSAPS listing
The bill for all the prescriptions for which reimbursement was claimed was 2,195,000 FF. 77.7% of this amount was reimbursed by the Assurance Maladie. For listed drugs (generic and reference drugs), the amount reimbursed was 178,429 FF, i.e. 10.5% of the total amount reimbursed. The average sum reimbursed per prescription dispensed was 31.54 FF for substituted drugs, 35.39 FF for prescribed generic drugs and 50.26 FF for reference drugs.
The substitution and the prescriptions of the generic drugs have respectively allowed an economy of 4.62% and 5.39% of the total amount reimbursed for listed drugs.
The savings in sums reimbursed by the Assurance Maladie could be increased to 29.6% if generic drugs were prescribed systematically and to 37.3% if systematic substitution of reference medicinal products took place. 
